(VIANEWS) – Globus Medical (GMED), Primoris Services Corporation (PRIM), Amgen (AMGN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Globus Medical (GMED)
111.4% sales growth and 4.21% return on equity
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Earnings Per Share
As for profitability, Globus Medical has a trailing twelve months EPS of $1.07.
PE Ratio
Globus Medical has a trailing twelve months price to earnings ratio of 50.9. Meaning, the purchaser of the share is investing $50.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.21%.
Volume
Today’s last reported volume for Globus Medical is 893795 which is 28.27% below its average volume of 1246200.
Moving Average
Globus Medical’s worth is above its 50-day moving average of $53.72 and higher than its 200-day moving average of $53.36.
2. Primoris Services Corporation (PRIM)
29.5% sales growth and 11.48% return on equity
Primoris Services Corporation, a specialty contractor company, provides a range of construction, fabrication, maintenance, replacement, and engineering services in the United States and Canada. It operates through three segments: Utilities, Energy/Renewables, and Pipeline Services. The Utilities segment offers installation and maintenance services for new and existing natural gas distribution systems, electric utility distribution and transmission systems, and communications systems. The Energy/Renewables segment provides a range of services, including engineering, procurement, and construction, as well as retrofits, highway and bridge construction, demolition, site work, soil stabilization, mass excavation, flood control, upgrades, repairs, outages, and maintenance services to renewable energy and energy storage, renewable fuels, petroleum, refining, and petrochemical industries, as well as state departments of transportation. The Pipeline Services segment offers a range of services comprising pipeline construction, maintenance, facility, and integrity services; installation of compressor and pump stations; and metering facilities for entities in the petroleum and petrochemical industries, as well as gas, water, and sewer utilities. The company was founded in 1960 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Primoris Services Corporation has a trailing twelve months EPS of $2.4.
PE Ratio
Primoris Services Corporation has a trailing twelve months price to earnings ratio of 16.22. Meaning, the purchaser of the share is investing $16.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.48%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 28, 2023, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 0.62%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 13% and positive 350% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.1%, now sitting on 5.53B for the twelve trailing months.
Yearly Top and Bottom Value
Primoris Services Corporation’s stock is valued at $38.94 at 10:22 EST, below its 52-week high of $39.20 and way higher than its 52-week low of $22.90.
3. Amgen (AMGN)
9.7% sales growth and 135.79% return on equity
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $12.49.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 22.45. Meaning, the purchaser of the share is investing $22.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 135.79%.
Volume
Today’s last reported volume for Amgen is 2531340 which is 12.53% below its average volume of 2894160.
Moving Average
Amgen’s value is below its 50-day moving average of $297.00 and higher than its 200-day moving average of $261.91.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 7.5% and a negative 8%, respectively.
Previous days news about Amgen(AMGN)
- The zacks analyst blog highlights NVIDIA, Visa, Amgen, chubb and paccar. According to Zacks on Thursday, 29 February, "Amgen has positive record of earnings surprises in recent quarters.(You can read the full research report on Amgen here >>>)Other noteworthy reports we are featuring today include Chubb Ltd. ", "The addition of Horizon Therapeutics has given Amgen a significant rare disease business. "
4. Webster Financial Corporation (WBS)
8.5% sales growth and 10.36% return on equity
Webster Financial Corporation operates as the bank holding company for Webster Bank, National Association that provides a range of financial services to individuals, families, and businesses in the United States. It operates through three segments: Commercial Banking, HSA Bank, and Consumer Banking. The Commercial Banking segment provides commercial real estate and equipment financing, business banking, asset-based lending, and commercial services; public sector finance; mortgage warehouse financing; treasury management services; credit, deposit, and cash flow management services; and wealth management solutions to business owners and operators, including trust, asset management, financial planning, insurance, retirement, and investment products, as well as derivative, treasury, accounts payable, accounts receivable, and trade products and services. The HSA Bank segment offers health savings accounts, health reimbursement arrangements, flexible spending accounts, and commuter services that are distributed directly to employers and individual consumers, as well as through national and regional insurance carriers, consultants, and financial advisors. The Consumer Banking segment provides consumer deposit and fee-based services, residential mortgages, home equity lines, secured and unsecured loans, and credit cards to consumers; and small business banking products, such as credit, deposit, and cash flow management to businesses and professional service firms. It also offers online and mobile banking services. Webster Financial Corporation was founded in 1935 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, Webster Financial Corporation has a trailing twelve months EPS of $4.91.
PE Ratio
Webster Financial Corporation has a trailing twelve months price to earnings ratio of 9.55. Meaning, the purchaser of the share is investing $9.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.36%.
Moving Average
Webster Financial Corporation’s worth is below its 50-day moving average of $49.48 and way above its 200-day moving average of $42.47.
Revenue Growth
Year-on-year quarterly revenue growth declined by 9.1%, now sitting on 2.5B for the twelve trailing months.
Sales Growth
Webster Financial Corporation’s sales growth is 2% for the current quarter and 8.5% for the next.
5. Regional Management Corp. (RM)
6.6% sales growth and 5.06% return on equity
Regional Management Corp., a diversified consumer finance company, provides various installment loan products primarily to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders in the United States. It offers small and large installment loans; and retail loans to finance the purchase of furniture, appliances, and other retail products. The company also provides insurance products, including credit life, credit accident and health, credit property, vehicle single interest, and credit involuntary unemployment insurance; collateral protection insurance; and property insurance, as well as reinsurance products. In addition, its loans are sourced through branches, centrally managed direct mail campaigns, digital partners, and retailers, as well as its consumer website. As of February 24, 2022, the company operated through a network of approximately 350 branches in 14 states. Regional Management Corp. was incorporated in 1987 and is headquartered in Greer, South Carolina.
Earnings Per Share
As for profitability, Regional Management Corp. has a trailing twelve months EPS of $1.66.
PE Ratio
Regional Management Corp. has a trailing twelve months price to earnings ratio of 12.67. Meaning, the purchaser of the share is investing $12.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.06%.
